Frunevetmab (Solensia) for Feline Osteoarthritis: Efficacy and Real-World Safety

Bottom line

• Frunevetmab is a felinized anti-nerve growth factor (anti-NGF) monoclonal antibody licensed for the alleviation of osteoarthritis (OA) pain in cats; it binds NGF and interrupts pain signaling upstream of prostaglandin pathways, a mechanism distinct from COX inhibition by NSAIDs.[1][3]
• Efficacy rests on a pivotal randomized, placebo-controlled, double-blind superiority trial (n = 275 cats): frunevetmab 1.0 mg/kg SC on days 0, 28, and 56 was superior to placebo on the client-specific outcome measures (CSOM) questionnaire at days 28 and 56 (NNT 9, effect size 0.3 at day 56), owner-assessed global response at days 28 and 56, and veterinarian-assessed joint pain at days 56 and 84.[3]
• Real-world, uncontrolled data reinforce a clinically meaningful benefit: in an observational study using a validated health-related quality-of-life (HRQL) instrument, cats improved significantly across all domains by day 14, exceeding the measure's minimum important difference.[1]
• Safety converges on a predominantly dermatological signal: skin disorders were significantly more frequent than placebo in the RCT (17.6% vs 8.6%),[3] and an FDA Animal Drug Adverse Events (ADAE) disproportionality analysis found skin reactions (pruritus, alopecia, dermatitis/eczema, skin ulceration, injection-site pain) as the most frequent and highest-strength signals.[2]
• The same ADAE analysis flagged unexpected, off-label signals — paresis, proprioceptive abnormalities, arthritis, and abnormal cytology — which are hypothesis-generating disproportionality findings, not incidence rates or established causation.[2]
• This page summarizes published evidence for licensed veterinary professionals. It is not a dosing protocol; confirm regimen, monitoring, and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Felinized anti-nerve growth factor (anti-NGF) IgG monoclonal antibody. Brand name Solensia (Zoetis).
• Mechanism: Binds and neutralizes nerve growth factor (NGF), a neurotrophin elevated in OA joint tissue that sensitizes nociceptors and drives peripheral and central sensitization. Blockade interrupts pain signaling upstream of the COX/prostaglandin cascade, making it pharmacologically complementary to NSAIDs.[3]
• Route and schedule: Subcutaneous injection at monthly intervals. The pivotal RCT dosed 1.0 mg/kg SC on days 0, 28, and 56 (effective dose range studied 1.0–2.8 mg/kg).[3]
• Indication: Alleviation of pain associated with osteoarthritis in cats.[1][3]
• Approval: US approval 2022; reporting volume in post-marketing surveillance has grown year over year since launch.[2]
• Contraindications / cautions: Follow current labeling. The product insert carries a note on neurological adverse effects derived from primate toxicity studies, and label-consistent dermatological reactions are recognized. Not a dosing guide — confirm the regimen for the individual patient against the label and formulary.

What the evidence shows

Evidence is organized below by the clinical question a practitioner is likely to ask. Each distinct study is presented once; date-stamps are inline.

Does it work? Controlled efficacy (the pivotal RCT)

The registrational evidence is a randomized, placebo-controlled, parallel-group, double-blind superiority trial in 275 client-owned cats with naturally occurring OA pain and mobility impairment (182 frunevetmab / 93 placebo). Cats received frunevetmab 1.0 mg/kg SC (or matched placebo) on days 0, 28, and 56.[3]

The primary outcome was the CSOM questionnaire, a validated owner-reported tool in which owners nominate three activities of daily living their cat struggles with and rate ability at each visit; the instrument was established in the earlier feline anti-NGF pilot proof-of-concept study.[4] Frunevetmab achieved statistically significant improvement over placebo on CSOM success rates and total scores at days 28 and 56 (NNT 9, standardized effect size 0.3 at day 56).[3] Owner-assessed global treatment response was significantly superior to placebo at days 28 and 56, and veterinarian-assessed joint pain (orthopedic examination score) reached significance at days 56 and 84 (effect size 0.18 at day 56).[3]

The delayed veterinarian-assessed response relative to the day-28 owner-reported response is clinically instructive: owner-detected functional improvement often precedes detectable change on point-in-time orthopedic examination in cats. As of July 2026, the Gruen 2021 dataset remains the pivotal controlled efficacy evidence, and no head-to-head trial against feline NSAIDs has been published.[3]

How much does it help in the real world? (observational quality of life)

An observational, real-world study complements the RCT by measuring HRQL outside a controlled setting. Using a validated instrument that generates domain scores for vitality, comfort, and emotional wellbeing, 56 cat owners completed repeated assessments through a study app while their cats received monthly SC frunevetmab.[1]

By day 14 there was a statistically significant improvement in all HRQL domains and in the physical wellbeing summary score, with continued improvement at later time points. Crucially, the overall improvement in domain scores exceeded the previously reported minimum important difference for the measure, which the authors interpreted as a clinically significant change rather than a merely statistical one.[1] Because this design lacked a placebo arm, it complements rather than replaces the controlled registration data — but the day-14 signal aligns directionally with the RCT's owner-reported benefit.

How does it compare to NSAIDs? (comparators and multimodal use)

Frunevetmab's value proposition is mechanistic and practical rather than head-to-head. By neutralizing NGF, it provides analgesia without the COX-mediated renal or gastrointestinal effects associated with chronic NSAID use, and its monthly SC dosing removes the daily-owner-administration burden.[3] This makes it a rational option in cats where NSAIDs are contraindicated or poorly tolerated — notably concurrent chronic kidney disease — and pharmacologically complementary to NSAID therapy in multimodal analgesia.

Two caveats are important. First, as of July 2026 no published randomized trial compares frunevetmab head-to-head with a feline NSAID (e.g., robenacoxib), so any "superiority" or "equivalence" claim over NSAIDs is unsupported.[3] Second, combining anti-NGF therapy with NSAIDs should be approached with the joint-safety signal (below) in mind, given the human-medicine experience with concurrent NGF-blockade plus NSAIDs.

Is it safe? (adverse-event profile — two data sources in agreement)

The safety picture is consistent across a controlled trial and a large post-marketing dataset, and the two are best read together.

Controlled-trial signal. In the RCT, overall adverse-event rates did not differ significantly between groups, but skin disorders as a collective category were significantly more frequent in frunevetmab-treated cats: 32/182 (17.6%) versus 8/93 (8.6%) with placebo.[3] Severity and specific manifestations were not detailed in the primary publication, but the direction is unambiguous.

Post-marketing signal. A disproportionality analysis of the FDA ADAE database (published in JVIM in early 2026) extracted 5,248 frunevetmab-specific reports from 33,378 total feline AE reports submitted January 2022–December 2024, applying four algorithms simultaneously (ROR, PRR, BCPNN, MGPS) and defining a signal as significant across all four.[2] Of cats with known demographics, 83.6% were >10 years old (the expected OA population), 53.7% of reports came from veterinarians, and median time to onset was 5 days (IQR 0–21). Nineteen significant AE signals emerged. Skin and subcutaneous tissue disorders dominated: highest-frequency signals were pruritus, unspecified skin disorders, alopecia, dermatitis/eczema, and unspecified skin lesions; highest signal strength (ROR) came from skin ulceration, unspecified skin disorders/lesions, injection-site pain, and dermatitis/eczema.[2]

Synthesis. Both sources point the same way: dermatological and injection-site events are the dominant, expected adverse effects, mechanistically plausible because NGF contributes to cutaneous sensory innervation and mast-cell activation. These events are already reflected in labeling. The practical implication is structured skin and injection-site monitoring at each monthly visit.

Are there signals beyond the label? (contested / hypothesis-generating findings)

Two clinically important questions are genuinely unsettled as of July 2026, and the evidence is presented here from each side.

Neurological signals (paresis, proprioceptive abnormalities). The ADAE analysis detected paresis (n = 78 reports, significant across all four algorithms) and proprioceptive abnormalities (n = 49) as disproportionate signals not currently enumerated in the package insert.[2] Supporting concern: the insert already carries a neurological caution based on primate toxicity studies, and in 2024 the FDA issued a Dear Veterinarian Letter regarding neurological adverse events with the canine anti-NGF antibody bedinvetmab — a plausible class read-across. Counterpoint / limiting interpretation: disproportionality reflects reporting patterns, cannot establish causality or incidence, and is vulnerable to confounding and stimulated reporting after the canine letter. The authors explicitly frame these as hypothesis-generating and in need of validation.[2] Neither the RCT nor the observational HRQL study reported a comparable neurological safety signal.[1][3]

Joint-related signals (arthritis / accelerated OA). The ADAE analysis also flagged an arthritis signal.[2] Supporting concern: in human medicine, anti-NGF agents (e.g., tanezumab) were associated with rapidly progressive osteoarthritis (RPOA), and an analogous rapidly progressive OA signal has been discussed for bedinvetmab in dogs — raising the question of whether NGF blockade can accelerate joint deterioration in cats. Counterpoint: an "arthritis" report in a population being treated for arthritis is confounded by indication, disproportionality cannot separate drug effect from progression of underlying disease, and no controlled feline data demonstrate accelerated joint destruction. This remains an open question.[2]

Abnormal cytology. Also detected as a significant but poorly characterized signal; its clinical meaning is unclear and warrants further study rather than any specific action.[2]

The consistent theme across all off-label signals: they are reporting-pattern observations that warrant clinical attention and pharmacovigilance, not confirmed drug effects.

Contraindications, precautions & PK

• Regimen (from the pivotal trial): 1.0 mg/kg SC on a monthly schedule; the studied effective dose range was 1.0–2.8 mg/kg.[3] Confirm the labeled dose and any weight banding against current product labeling for the individual patient — this page is not a dosing protocol.
• Onset/kinetics (functional, not formal PK here): owner-reported functional benefit was measurable by day 14 in real-world use and statistically robust by day 28 in the RCT; veterinarian-detectable examination change lagged to days 56–84.[1][3]
• Dermatological precaution: anticipate and monitor for pruritus, alopecia, dermatitis/eczema, skin ulceration, and injection-site reactions; the RCT and ADAE data agree these are the dominant events.[2][3]
• Neurological precaution: the label already notes neurological adverse effects from primate toxicity studies; post-marketing paresis/proprioceptive signals reinforce baseline and interval neurological screening, interpreted cautiously.[2]
• Special populations: the target population is older cats (>10 years predominate in real-world reporting), frequently with comorbidities; frunevetmab's non-COX mechanism is attractive where CKD or GI intolerance limits NSAIDs, but concurrent NSAID use should weigh the joint-safety discussion above.[2][3]
• What is NOT established: incidence rates for any post-marketing signal, causality for paresis/arthritis/abnormal cytology, and any comparative efficacy or safety claim versus feline NSAIDs.[2][3]

Practical decision support

This section summarizes the published evidence base for licensed practitioners and is not clinical guidance; tailor all decisions to the individual cat, current labeling, and a formulary.

• Candidate selection: older cats with confirmed OA pain and mobility impairment, particularly where daily oral dosing is impractical or chronic NSAIDs are contraindicated/intolerated. The controlled NNT of 9 at day 56 is in a clinically meaningful range for chronic pain therapeutics.[3]
• Owner counseling at initiation: set expectations that functional improvement is often owner-visible within ~2 weeks;[1] explain the dermatological/injection-site profile and what to report between visits.[2][3]
• Monitoring at every recheck: examine injection sites and skin for reactions beyond transient injection-site pain (ulceration, persistent erythema warrant reporting); perform a brief neurological assessment (proprioceptive testing, gait quality, activity/coordination change); and assess for new lameness that could prompt baseline/follow-up joint evaluation.[2][3]
• Pharmacovigilance: report unexpected adverse events to the FDA ADAE portal or to Zoetis; the dataset's value scales with reporting.[2][5]
• Evidence gaps to communicate honestly: no head-to-head NSAID comparison, and post-marketing neurological/joint signals are unconfirmed as of July 2026.[2][3]

Frequently Asked Questions

(Rendered from the FAQ metadata.)

Changelog

• 2026-06-05: Hub first published (real-world HRQL + FDA ADAE safety overview).
• 2026-07-06: Consolidated the dated dispatch spokes into this evergreen hub — folded in the Gruen 2021 pivotal RCT (n=275; CSOM/owner/vet endpoints, 17.6% vs 8.6% skin AEs) and the Gruen 2016 CSOM pilot from the RCT spoke, and the full FDA ADAE disproportionality dataset (5,248 reports; 19 signals; paresis/proprioceptive/arthritis/abnormal-cytology) from the AE-signals spoke. Reorganized evidence by clinical question, split the off-label signals into a contested-evidence section with both sides, and added dedicated Contraindications/PK and Practical decision support sections. All citations verified and de-duplicated (each study appears once).